--- title: Publications | Beyond Cancer description: Publications | Beyond Cancer --- # Publications #### Poster Presentation: Survival Benefit in Salvage Patients With Intratumoral Ultra-High Concentration Nitric Oxide Gas Injection in Cutaneous and Subcutaneous Solid Tumors in a Phase 1 Study ##### Meirovitz, A. et al. April 17, 2026 [ View Publication ](https://beyondcancer.com/hubfs/AACR2026_304_BeyondCancer_Final.pdf?hsLang=en) #### Poster Presentation: Intratumoral Administration of Low Volume Ultra-High Concentration Nitric Oxide and Immune Checkpoint Inhibitors in CT26 Tumor-Bearing Mice ##### Dirbas, F. et al. November 8, 2024 [ View Publication ](https://beyondcancer.com/hubfs/BeyondCancer_February2025/pdfs/SITC_11124_Final.724.pdf?hsLang=en) #### Poster Presentation: Intratumoral Administration of Low Volume Ultra High-Concentration Nitric Oxide andAnti-rPD-L1 Treatment Leads to Prolonged Survival in MAT B III Tumor-Bearing Rats ##### Pegram, M. et al. November 8, 2024 [ View Publication ](https://beyondcancer.com/hubfs/BeyondCancer_February2025/pdfs/SITC_11124_Final.723.pdf?hsLang=en) #### Beyond Cancer Presents First-in-Class Clinical Data Showing an Immunogenic Response in Subjects with r/r Unresectable Solid Tumors Treated with Ultra-High Concentration Nitric Oxide (UNO) ##### ASCO June 3, 2024 [ View Publication ](https://beyondcancer.com/hubfs/BeyondCancer_February2025/pdfs/20240531-BC.ASCO_.vW_.pdf?hsLang=en) #### Poster Presentation: A Phase 1, Multi-center, Safety, Feasibility, and Preliminary Efficacy Study Evaluating a Single Dose of UNO101 in Relapsed or Refractory, Unresectable, Primary, or Metastatic Cutaneous and Subcutaneous Malignancies ##### Frederick M. Dirbas, et al. May 31, 2024 [ View Publication ](https://beyondcancer.com/hubfs/BeyondCancer_February2025/pdfs/ASCO_52824Final_Printv2.pdf?hsLang=en) #### Poster Presentation: Phase 1 Study of Ultra-High Concentration Nitric Oxide (UNO) in Relapsed or Refractory, Unresectable, Primary, or Metastatic Cutaneous and Subcutaneous Malignancies ##### Dirbas F., et al November 3, 2023 [ View Publication ](https://beyondcancer.com/hubfs/BeyondCancer_February2025/pdfs/2023-10-30-SITC_Poster_Final.pdf?hsLang=en) #### Abstract: Phase 1 study of ultra-high concentration nitric oxide (UNO) in relapsed or refractory, unresectable, primary, or metastatic cutaneous and subcutaneous malignancies ##### Meirovitz, A. et al October 31, 2023 [ View Publication ](https://beyondcancer.com/hubfs/BeyondCancer_February2025/pdfs/SITC_Abstract_Posting103023_BCWebsite.pdf?hsLang=en) #### Manuscript: Gaseous nitric oxide tumor ablation induces an anti-tumor abscopal effect ##### Hila Confino et al October 17, 2023 [ View Publication ](https://doi.org/10.3390/cells12202439) #### Poster: Ultra-High Concentration Nitric Oxide (UNO) Enhances Anti-CTLA-4 Treatment Activity and Induces a Durable Anti-Tumor Immune Response ##### Sela, Y. et al. October 14, 2023 [ View Publication ](https://beyondcancer.com/hubfs/BeyondCancer_February2025/pdfs/MOA-poster-EORTC-vFinal-5.pdf?hsLang=en) #### Poster: Intratumoral Administration of Ultra High-Concentration Nitric Oxide (UNO) and Anti PD-1Treatment Leads to High Tumor Regression Rates and Prolonged Survival in Tumor-Bearing Mice ##### Epshtein, Y. et al. October 12, 2023 [ View Publication ](https://beyondcancer.com/hubfs/BeyondCancer_February2025/pdfs/AACR-NCI-EORTC-poster_combination-studies.vFINAL.pdf?hsLang=en) #### Abstract: Ultra-High Concentration Nitric Oxide (UNO) Enhances Anti-CTLA-4 Treatment Activity and Induces a Durable Anti-Tumor Immune Response ##### Sela Y. et al October 4. 2023 [ View Publication ](https://beyondcancer.com/hubfs/BeyondCancer_February2025/pdfs/EORTC_AACR_NCI_2023_2.mp_.pdf?hsLang=en) #### Abstract: Intratumoral Administration of Ultra High-Concentration Nitric Oxide (UNO) and Anti PD-1 Treatment Leads to High Tumor Regression Rates and Prolonged Survival in Tumor-Bearing Mice ##### Epshtein Y. et al October 4. 2023 [ View Publication ](https://beyondcancer.com/hubfs/BeyondCancer_February2025/pdfs/EORTC_AACR_NCI_2023_1.pdf?hsLang=en) #### Poster: Intratumoral Administration of Ultra High-Concentration Nitric Oxide (UNO) is more Efficacious than anti-mPD-1 Therapy in 4T1 Tumor-Bearing Mice ##### Confino H et al April 19, 2023 [ View Publication ](https://beyondcancer.com/hubfs/BeyondCancer_February2025/pdfs/4T1-Poster-for-AACR-BC-format_16APR2023_FINAL.pdf?hsLang=en) #### Poster: Short-Term Exposure of Cancer Cells to Ultra-High Concentrations of Nitric Oxide (UNO) Activates the mPD-1/mPD-L1 Axis and Immune Responses ##### Confino H et al April 19, 2023 [ View Publication ](https://beyondcancer.com/hubfs/BeyondCancer_February2025/pdfs/PD-L1-poster-for-AACR_2023_16APR2023-FINAL.pdf?hsLang=en) #### Abstract: Short-Term Exposure of Cancer Cells to Ultra-High Concentrations Nitric Oxide Induces PDL-1 Upregulation ##### Confino H et al April 19, 2023 [ View Publication ](https://beyondcancer.com/hubfs/BeyondCancer_February2025/pdfs/PD-L1-Upregulation-and-Ultra-High-Concentration-of-Nitric-Oxide.final_.pdf?hsLang=en) #### Abstract: Intratumoral Administration of Ultra High-Concentration Nitric Oxide (UNO) is more Efficacious than Anti-PD1 Therapy in 4T1 Tumor-Bearing Mice ##### Confino H et al April 19, 2023 [ View Publication ](https://beyondcancer.com/hubfs/BeyondCancer_February2025/pdfs/Anti-PD1-and-NO-in-4T1-model.final_.pdf?hsLang=en) #### Manuscript: Gaseous Nitric Oxide Tumor Ablation Induces an Anti-Tumor Abscopal Effect ##### Confino H et al December 13, 2022 [ View Publication ](https://cancerci.biomedcentral.com/articles/10.1186/s12935-022-02828-z) #### Poster Presentation: Intratumoral Administration of High-Concentration Nitric Oxide and Anti PD-1 Treatment Leads to Higher Tumor Regression Rates and Prolonged Survival in CT26 Tumor-Bearing Mice ##### Confino H et al November 10, 2022 [ View Presentation ](https://beyondcancer.com/hubfs/BeyondCancer_February2025/videos/STIC_ePoster-2022.mp4?hsLang=en) #### Poster: Intratumoral Administration of High-Concentration Nitric Oxide and Anti PD-1 Treatment Leads to Higher Tumor Regression Rates and Prolonged Survival in CT26 Tumor-Bearing Mice ##### Confino H et al November 10, 2022 [ View Publication ](https://beyondcancer.com/hubfs/BeyondCancer_February2025/pdfs/__SITC_Poster_2022.pdf?hsLang=en) #### Abstract: Intratumoral Administration of High-Concentration Nitric Oxide and Anti PD-1 Treatment Leads to Higher Tumor Regression Rates and Prolonged Survival in CT26 Tumor-Bearing Mice ##### Confino H et al November 10, 2022 [ View Publication ](https://beyondcancer.com/hubfs/BeyondCancer_February2025/pdfs/Combination-abstract-SITC2022_final-1.pdf?hsLang=en) #### Poster: Ultra-high concentrations of gaseous nitric oxide show rapid cytotoxic capabilities against colon, breast, pancreatic and other cancer cells in vitro. ##### Confino H et al April 11, 2022 [ View Publication ](https://beyondcancer.com/hubfs/BeyondCancer_February2025/pdfs/In-vitro_PDF_3230_final1.pdf?hsLang=en) #### Poster: Single intra-tumoral injection of gaseous nitric oxide induces an adaptive immune response in a mouse CT-26 solid tumor model ##### Confino H et al April 11, 2022 [ View Publication ](https://beyondcancer.com/hubfs/BeyondCancer_February2025/pdfs/MOA_PDF_2940_final.pdf?hsLang=en) #### American Association for Cancer Research (AACR) Annual Meeting 2022 ##### Confino H et al: Single intra-tumoral injection of gaseous nitric oxide induces an adaptive immune response in a mouse CT-26 solid tumor model April 11, 2022 **Conclusion:** Intra-tumoral injection of ultra-high concentrations of NO at 20,000 and 50,000 ppm gNO led to increased recruitment of lymphocytes and T cells, B cells, macrophages and dendrocytes to the primary tumor. Increased T cells and B cells were detected in the spleen and blood 21 days post NO treatment. Decreased pMDSCs were detected in the spleen 21 days post NO treatment. The data suggest that gNOinduced innate and adaptive immune cell populations, and the reduction of immune suppressor cells, are indicative of an anti-tumor immune response that underlies the rejection of secondary tumors in gNO-treated mice. [ Watch ](https://beyondcancer.com/hubfs/BeyondCancer_February2025/videos/__MOA-ePoster_2940_final.mp4?hsLang=en) #### American Association for Cancer Research (AACR) Annual Meeting 2022 ##### Confino H et al: Ultra-high concentrations of gaseous nitric oxide show rapid cytotoxic capabilities against colon, breast, pancreatic and other cancer cells in vitro April 11, 2022 **Conclusion:** Exposure of human ovarian and pancreatic cancer cell lines and mouse lung, melanoma, colon and breast cancer cell lines to 10,000 ppm –100,000 ppm gNOresulted in a dose dependent cytotoxic response. Higher concentrations lead to near instant cell death. Lower concentrations require a longer exposure period to elicit cell death. No viable cells were detected after exposure to 50,000 ppm gaseous NO for 1 minute. Together with the known ability of NO to activate and recruit the immune system, these results suggest that gNOmay be a potent therapeutic agent for tumor treatment across a range of tumor types. [ Watch ](https://beyondcancer.com/hubfs/BeyondCancer_February2025/videos/In-vitro-ePoster_3230_final_1.mp4?hsLang=en) #### American Association for Cancer Research (AACR) Conference on Tumor Immunology and Immunotherapy ##### Confino H et al: Nitric oxide tumor ablation stimulates an anti-tumor immune response in mice October 19-20, 2020 [ Watch ](https://beyondcancer.com/hubfs/BeyondCancer_February2025/videos/Confino_Hila_Nitric-Oxide-Tumor-Ablation_OCT16.mp4?hsLang=en) #### 2020 North American Conference on Lung Cancer ##### Confino H et al: Nitric oxide lung cancer active vaccination October 16, 2020 **Conclusion:** Gaseous nitric oxide (gNO) treatment results in dose- and time-dependent inhibition of lung cancer cell proliferation and reduced viability in vitro. Treatment of primary LLC1 lung tumors in mice with gNO at a dose of 50,000 ppm for 10 minutes results in no uptake of a challenge tumor implanted up to 14 days later. No unanticipated mortality or signs indicating distress were noted in the animals. These preliminary data suggest that our innovative gNO-based treatment may treat lung tumors locally and their distant metastases systemically, potentially via stimulation of an anti-tumor immune response. [ View Publication ](https://beyondcancer.com/hubfs/BeyondCancer_February2025/pdfs/NACLC2020_POSTER_88_Confino_Hila.pdf?hsLang=en) #### American Association for Cancer Research Virtual Annual Meeting II ##### Confino H et al: Gaseous nitric oxide at high concentration is a powerful anti-tumor agent both in-vitro and in-vivo June 22, 2020 **Conclusion:** Our data demonstrate the potential utility of gaseous nitric oxide (gNO) as a treatment for cancer. In the current work, gNO at high concentrations showed a significant cytotoxic effect on cancer cells in vitro and in vivo. Moreover, our findings may indicate that tumor ablation with gNO stimulates an anti-tumor immune response. [ View Publication ](https://beyondcancer.com/hubfs/BeyondCancer_February2025/pdfs/Poster_6371_final.pdf?hsLang=en) ## A Cancer Treatment with a Powerful Systemic Response Our Approach